ArticleScientific reports2025
Effectiveness of local Tocilizumab administration in mitigating alveolar bone loss and inflammation in experimental periodontitis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
To examine the impact of locally applied Tocilizumab (TCZ), an anti-interleukin-6 receptor antibody, on experimental periodontitis. 50 Wistar male rats were divided into three groups: (1) Healthy (n = 10), (2) Experimental Periodontitis (n = 20), and (3) Experimental Periodontitis + TCZ (n = 20). The animals received an intrapapillary injection of TCZ (2 mg/kg). After three days, periodontitis was induced by placing a ligature around the upper left 2nd molar for ten days. In euthanasia, blood, maxillae, and gingival samples were removed for biochemical, microtomography, histologic, immunohistochemistry, cytokine assay and RT-qPCR analyses. TCZ was able to attenuate linear alveolar bone loss (p < 0.05) and the loss of the number of bone trabeculae (p < 0.05), and to reduce the severity of inflammation (p < 0.05). Its local administration decreased gingival tissue levels of IL-6 and TNF-α (p < 0.05), the intensity of RANKL immunostaining (p < 0.0001) and mRNA expression of SOD (p < 0.001) and GPx (p < 0.01). These findings suggest the anti-inflammatory efficacy of Tocilizumab administered in periodontitis. Cytokines play a major role in destroying periodontal support tissue during periodontitis. Inhibition of IL-6 receptor demonstrated to reduce periodontal inflammation and bone loss, and may be considered as an adjunctive approach in refractory or severe periodontitis cases that do not adequately respond to conventional therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.